Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes

Rhea-AI Filing Summary

Cadrenal Therapeutics Chairman and CEO Quang Pham, a more than 10% owner, reported an open-market sale of 7,400 shares of common stock on June 29, 2026 at a weighted average price of $3.03 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025.

Following the sale, Pham directly holds 98,589 shares of Cadrenal common stock. He also has indirect ownership of 200,000 shares held by The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power and his child is the sole beneficiary.

Insider Trade Summary 10b5-1

Net Seller: 7,400 shares ($22,422)

Net Sell 2 txns

Insider Pham Quang X

Role Chairman and CEO

Sold 7,400 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,400	$3.03	$22K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 98,589 shares (Direct); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (1)

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Key Figures

Shares sold: 7,400 shares Weighted average sale price: $3.03 per share Direct holdings after sale: 98,589 shares +2 more

5 metrics

Shares sold 7,400 shares Open-market sale on June 29, 2026

Weighted average sale price $3.03 per share Multiple trades between $3.00 and $3.13

Direct holdings after sale 98,589 shares Common stock directly owned post-transaction

Indirect trust holdings 200,000 shares Held by The PVBQ Living Trust

Trading plan adoption date September 25, 2025 Rule 10b5-1 trading arrangement

Key Terms

Rule 10b5-1 trading arrangement, weighted average price, The PVBQ Living Trust, voting and dispositive power

4 terms

Rule 10b5-1 trading arrangement regulatory

"sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

The PVBQ Living Trust financial

"The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares"

voting and dispositive power regulatory

"has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 09:52 PM Accepted by SEC EDGAR 07/01/2026 - 09:52 PM Learn about SEC filing dates

FAQ

What insider transaction did Cadrenal Therapeutics (CVKD) report for Quang Pham?

Cadrenal Therapeutics reported that Chairman and CEO Quang Pham sold 7,400 shares of common stock. The transaction occurred on June 29, 2026 and was reported on a Form 4 insider trading filing with the Securities and Exchange Commission.

At what price did Quang Pham sell Cadrenal Therapeutics (CVKD) shares?

Quang Pham sold the 7,400 Cadrenal shares at a weighted average price of $3.03 per share. A footnote explains the shares were sold in multiple trades between $3.00 and $3.13, with detailed trade data available on request.

How many Cadrenal Therapeutics (CVKD) shares does Quang Pham hold after this sale?

After the sale, Quang Pham directly owns 98,589 shares of Cadrenal common stock. In addition, a separate Form 4 entry shows he indirectly holds 200,000 shares through The PVBQ Living Trust, where he has sole voting and dispositive power.

Was Quang Pham’s Cadrenal Therapeutics (CVKD) share sale under a 10b5-1 plan?

Yes. A footnote states the 7,400-share sale was made under a Rule 10b5-1 trading arrangement. This pre-arranged plan was adopted on September 25, 2025, meaning the trades were scheduled in advance rather than decided at the time of sale.

What is The PVBQ Living Trust’s role in Quang Pham’s Cadrenal (CVKD) holdings?

The filing shows 200,000 Cadrenal shares held indirectly through The PVBQ Living Trust. Quang Pham is the trustee with sole voting and dispositive power, while his child is the trust’s sole beneficiary, giving him control over those shares.

What does the weighted average price disclosure mean for the Cadrenal (CVKD) insider sale?

The filing lists a $3.03 weighted average price because the 7,400 shares were sold in multiple trades between $3.00 and $3.13. The insider has offered to provide the exact breakdown of shares at each price upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FLORIDA 32082

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S		7,400(1)	D	$3.03(2)	98,589	D
Common Stock								200,000	I	The PVBQ Living Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Quang X. Pham	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)